文献速递脑血管病

人工智能与新型试验设计在急性缺血性卒中中的机遇与挑战

Artificial Intelligence and Novel Trial Designs for Acute Ischemic Stroke: Opportunities and Challenges.
PubMed 文献 · Stroke · 2025-09-30

2025年3月28日Stroke Treatment Academic Industry Roundtable XIII会议召开研讨会,汇聚卒中医生、研究者与业界代表,讨论人工智能与新型试验设计在急性卒中试验中的当前应用与未来机会。AI已在卒中影像治疗中发挥重要作用,平台试验可共享对照提高效率,但需理解人机协同与局限性。

要点

  • AI在急性卒中影像中已广泛应用,未来将在临床 care 与研究中发挥更大作用。
  • 平台试验通过共享对照同时回答多个科学问题,提高效率但增加工作流程复杂性。
  • 未来急性缺血性卒中试验应尽可能融入实用性与以患者为中心的设计元素。

核心结论

  • AI模型与平台、实用性及以患者为中心的试验设计是回答重要临床问题的新工具,但理解其运作方式、最佳用途与局限性对加速卒中新疗法成功至关重要。

研究设计与样本

  • Stroke Treatment Academic Industry Roundtable XIII会议于2025年3月28日召开研讨会,汇聚卒中医生、研究者与业界代表讨论AI与新型试验设计在急性卒中试验中的应用与未来机会。

主要发现

  • AI已在急性卒中影像治疗中发挥重要作用,并有望在未来数年对临床 care 与研究试验产生更大影响。
  • AI训练数据的质量与理解、确保训练成功所需的人工要素以及床旁临床医生与试验者这些「环路中的人」对最大化AI在临床实践与试验中的效果必不可少。
  • 平台试验通过共享对照在相同试验结构中同时回答多个科学问题,提高效率并可能缩短回答重要临床科学问题所需时间,但也可能给标准工作流程引入复杂性。

临床怎么用

  • 未来急性缺血性卒中临床试验应尽可能融入实用性与以患者为中心的试验设计元素。
  • 实用试验旨在评估治疗在常规临床 care 中实施时的效果,而非理想化条件下的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Stroke Treatment Academic Industry Roundtable convened a workshop regarding artificial intelligence (AI) and innovative clinical trial designs during the Stroke Treatment Academic Industry Roundtable XIII meeting on March 28, 2025. This forum brought together stroke physicians and researchers, and industry representatives to discuss the current use and future opportunities for AI and novel trial designs in acute stroke trials. AI already plays a substantial role in the treatment of acute stroke with regards to imaging but is poised to have a much larger impact in clinical care and research trials over the coming years. The quality and understanding of the data are used to train the AI, the human element needed to ensure training is successful, and the clinician and trialist at the bedside, the humans "in the loop," will be necessary to maximize AI's effectiveness in clinical practice and trials. Platform trials address multiple scientific questions in an area of medicine simultaneously within the same trial structure by sharing controls across multiple interventions. While platform trials increase efficiency and potentially decrease the time needed to answer important clinical scientific questions, they also can introduce complexity to standard workflows. Future acute ischemic stroke clinical trials should incorporate elements of pragmatic and patient-centered trial design when possible. Pragmatic trials aim to assess the effectiveness of treatments when they are implemented into routine clinical care rather than under idealized conditions. AI models and platform, pragmatic, and patient-centered trial designs are new tools to answer important clinical questions, but understanding how they work, their best uses, and their limitations is critical for accelerating successful new treatments for stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Broderick JP, Mistry EA, Wechsler PM, et al. Artificial Intelligence and Novel Trial Designs for Acute Ischemic Stroke: Opportunities and Challenges. Stroke. 2025. PMID: 41025236. doi:10.1161/STROKEAHA.125.052146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。